I thought this very recent news below on Dendreon might be of interest to PRR shareholders since the details of this announcement could easily apply to PRR in the foreseeable future!
cheers birdseye
Dendreon tripling workforce ahead of expected vac launch
April 1 2010 By John Carroll
Over the years Seattle-based Dendreon made a global name for itself as it developed one of the world's first therapeutic vaccines. It's also advanced the careers of scores of biotech executives who have gone on to a wide variety of other drug developers.
"Anybody who can sustain through what Dendreon has sustained--it's a good sign of who they are," Martin Simonetti, the former chief financial officer at Dendreon and now CEO of Seattle-based VLST, tells Xconomy's Luke Timmerman. ----------There were a lot of good people that made good things happen."
---- . The company tells Xconomy that its workforce, 200 a year ago, is growing to 600 this year AS IT PREPARES FOR THE HIGHLY ANTICIPATED REGULATORY DECISION ON PROVENGE.
